.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical evidence explores the utilization of adjuvant radiation for PDAC. According to a large-scale database study evaluating the RTOG 0848 protocol, utilization of this modality has significantly declined over the last two decades. While adjuvant radiation rates dropped from 45% to 12%, neoadjuvant radiation rates simultaneously tripled. However, researchers identified that patients with specific pathologic features still derive substantial benefits from this treatment.
The study utilized the National Cancer Database to analyze survival outcomes in a cohort mimicking the RTOG 0848 trial criteria. Notably, clinicians observed improved overall survival in patients with node-negative disease and positive surgical margins who received adjuvant radiation for PDAC. Specifically, median survival increased from 23.0 to 28.6 months in this high-risk group. Consequently, positive margins and nodal involvement remain the primary predictors for radiation receipt. Therefore, these findings suggest that while broad application is decreasing, targeted use remains vital for specific subgroups. Furthermore, this real-world data reinforces the importance of careful patient selection in modern oncological practice.
While overall usage is declining in favor of neoadjuvant approaches, it remains highly beneficial for specific subgroups, particularly those with node-negative disease and positive surgical margins.
The strongest predictors for receiving adjuvant radiation include positive surgical margins and nodal disease, as these factors typically indicate a higher risk of local recurrence.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Professional medical consultations are necessary for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
1. Dickey EM et al. Trend of Adjuvant Radiation in Resected Pancreatic Ductal Adenocarcinoma: Evaluation of RTOG 0848 with a Large National Database. J Gastrointest Cancer. 2026 May 25. doi: undefined. PMID: 42184090.
2. Abrams RA, et al. Results of the NRG Oncology/RTOG 0848 adjuvant chemotherapy question: erlotinib + gemcitabine for resected cancer of the pancreatic head. J Clin Oncol. 2020;38(27):3139-3147.
3. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 2.2024.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A database study reveals declining rates of adjuvant radiation for pancreatic cancer, though survival benefits persist in specific node-negative patient gro...
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
